Latest news with #S
New Indian Express
5 days ago
- Health
- New Indian Express
RMRC Bhubaneswar develops advanced malaria vaccine, ready for tech transfer
BHUBANESWAR: In a significant breakthrough, a team of researchers led by the Regional Medical Research Centre (RMRC), Bhubaneswar, has developed a novel and advanced malaria vaccine that can prevent Plasmodium falciparum infection in humans and community transmission. The new recombinant, chimeric multi-stage vaccine code-named AdFalciVax has been designed to protect against the deadliest malaria parasite in humans. It is now ready for technology transfer to manufacturers for production, clinical trials and its commercialisation. Currently, two malaria vaccines are available and cost in a range of `250 to `830 per dose. The efficacy rate is between 33 per cent and 67 per cent. Unlike existing WHO-recommended vaccines RTS,S/AS01 (Mosquirix) and R21/Matrix-M, AdFalciVax offers dual-stage protection and is cost-effective. Scientist-D at RMRC Dr Susheel Singh said the new vaccine can prevent human infection and interrupt transmission in the community. 'AdFalciVax uses a full-length PfCSP, a major protein found in Pf, for broader protection and includes a novel fusion of Pfs230 and Pfs48/45 proteins to produce strong antibodies that stop the transmission,' he said. What makes AdFalciVax stand out among the existing vaccines is its exceptional pharmaceutical stability. The formulation remains potent for over nine months at room temperature, eliminating the need for costly cold chain logistics, which continue to be a major bottleneck in vaccine distribution across remote and resource-limited regions. According to the researchers, the vaccine has been developed with the help of cutting-edge protein engineering using Lactococcus lactis, a safe bacterial host. The pre-clinical validation of the technology has been conducted by RMRC in collaboration with National Institute of Malaria Research (NIMR) and National Institute of Immunology (NII), New Delhi. RMRC director Dr Sanghamitra Pati said, 'The vaccine's efficacy was sustained for over four months post-boost, which translates to over a decade of protection in humans.' Meanwhile, Indian Council of Medical Research (ICMR), New Delhi has invited expressions of interest from the eligible organisations, companies and manufacturers for transfer of technology and commercialisation.
Yahoo
11-07-2025
- Business
- Yahoo
Jaffa resident turns Iranian missile attack rubble into profit
While families wait to return to their homes, destroyed in the Iranian missile attack, some have seized an opportunity for quick income amid the devastation. A Jaffa resident has been collecting aluminum scraps from the wreckage of buildings that were destroyed by Iranian missiles to sell them to turn a profit, he told Walla on Thursday. There are many families still waiting to return to their homes, destroyed in the Iranian missile attack. S., a resident of Jaffa, walks through the wreckage, collecting aluminum scraps and selling them to traders, earning thousands of shekels a day. "I look like a laborer, wearing an orange vest, and no one asks questions," he says. As the country heals its wounds and evacuees await grants and compensation, some have already moved on to the next stage. In dozens of streets affected inBat Yam, Rishon Lezion, and Tel Aviv, where houses have been reduced to piles of concrete and dust—S. roams daily, collecting anything made of aluminum: windows, doors, frames. "The money is just lying on the ground," he says. "I sell the aluminum for 4.5 shekels per kilogram. On a good day, I earn 2,000 shekels; on a weak day, 500. I finish collecting, traders come, weigh what I've gathered, and pay me on the spot. It's a good, respectable daily wage." When asked about the law, S. explains that he sets clear boundaries for himself. "If I know who it belongs to, I ask. If they don't give it to me, I move on. But if there's no address, no tenant, nothing, I take it. Simple as that," he says. According to him, he's not the only one collecting: "Others are doing it too, but what's annoying is that there are stingy Israelis who prefer to collect on their own and sell it, instead of giving it to me." When asked whether he's referring to residents who've experienced the destruction firsthand and are now forced to wander between hotels and absorption centers, S. doesn't hesitate. "Yes, but so what? They're covered, they'll get money from the state or whoever needs to pay them. I found treasure here. Its not a crime—just a good way to make a living."
Yahoo
28-06-2025
- Business
- Yahoo
Jefferies Trims SentinelOne (S) Price Target, Maintains Buy Rating
SentinelOne, Inc. (NYSE:S) is one of . Jefferies analyst Joseph Gallo has lowered the firm's price target on SentinelOne, Inc. (NYSE:S) to $23 from $25, while maintaining a Buy rating on the shares. The adjustment reflects a broader reduction in price targets across Jefferies' U.S. software coverage, prompted by recent multiple compression and early signs of softening macroeconomic conditions affecting deal-making in the technology sector. Gallo pointed out that these factors could lead to what he describes as another 'mullet' year for software companies, characterized by a challenging first half followed by a stronger second half. Despite this outlook, Jefferies has not yet lowered its earnings estimates for SentinelOne, choosing instead to await further data from upcoming first-quarter checks. The analyst also noted that SentinelOne's recent guidance assumed no significant improvement in market conditions, underscoring the cautious tone from management. As uncertainty continues, many investors appear to be holding back, adopting a wait-and-see approach to gauge how the evolving environment will affect technology spending and deal activity. While the cautious stance has led to a tempered near-term outlook, Jefferies remains positive on SentinelOne's longer-term prospects, keeping a Buy rating on the stock. While we acknowledge the potential of S to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than S and that has 100x upside potential, check out our report about this cheapest AI NEXT: 10 Best Small Cap Tech Stocks With Biggest Upside Potential and . Disclosure: None.
Time of India
26-06-2025
- Business
- Time of India
GSK, Bharat Biotech to slash malaria vaccine prices to under $5 per dose by 2028
Representative Image HYDERABAD: Vaccine maker Bharat Biotech International Ltd and British biopharma giant GSK plc will be slashing the prices of the world's first malaria vaccine - RTS,S or Mosquirix - by over half to less than $5 per dose by 2028 as part of their pledges to Gavi's replenishment process for 2026-2030. The proposed price reduction will be driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins, they said in a joint statement on Wednesday.
United News of India
25-06-2025
- Health
- United News of India
World's first kids' malaria vaccine price to be less than USD 5 by 2028
Hyderabad, June 25 (UNI) Bharat Biotech International Limited (BBIL) and GSK plc, a Global Pharma Company, today announced their commitment to Gavi, the Vaccine Alliance (Gavi), in the continued roll out of the world's first malaria vaccine. Bharat Biotech will be reducing the price of world first malaria vaccine 'RTS.S, developed by GSK, PATH and partners, by more than half, to less than $5 progressively by 2028. This price reduction is driven by process improvements, expanded production capacity, cost- effective manufacturing, and minimal profit margins, Hyderabad based vaccine maker BBIL said in a release here. The announcement forms part of pledges to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies. RTS,S was the first malaria vaccine recommended by the World Health Organisation (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency, and to undertake the planned technology transfer to Bharat Biotech. In parallel, Bharat Biotech has invested over $200 million in new, higher- output manufacturing facilities, product development and technology transfers. These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete. Through Gavi support, RTS,S expected to be rolled out in 12 endemic countries in Africa through routine immunisation programmes by end of 2025 This has only been possible through the critical work that GSK has undertaken with Bharat Biotech, PATH, together with the WHO, implementing countries, MedAccess and Gavi, to help deliver access to life-saving malaria prevention for children in endemic countries in Africa. BBIL Executive Chairman Dr. Krishna Ella, said: "Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria'. In a recent evaluation of impact by the WHO of the Malaria Vaccine Implementation Programme (MVIP) in Ghana, Kenya and Malawi, where over 2 million children received the RTS,S vaccine between 2019 and 2023, the WHO reported a 13 percent reduction in all-cause mortality and a 22 percent reduction in hospitalisations of severe malaria among children age- eligible for vaccination during this period1. When administered seasonally in regions with high malaria transmission, alongside seasonal malaria chemoprevention, the two malaria vaccines recommended by the WHO, have been shown to prevent around 75 percent of malaria episodes. UNI KNR SSP
